{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:24:13Z","timestamp":1783617853161,"version":"3.55.0"},"reference-count":24,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,1,3]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"\n Aims<\/jats:title>\n \n Historically, there has been no consensus on the diagnostic classification of high-grade B-cell lymphoma (HGBCL) with morphological features of Burkitt lymphoma (BL) but no\n MYC<\/jats:italic>\n gene rearrangement (\n MYC<\/jats:italic>\n -negative). The 2016 WHO classification of tumours of haematopoietic and lymphoid tissues has shed some light on this field with the modification of the grey-zone lymphoma with features intermediate between BL and diffuse large B-cell lymphoma, and the creation of several new entities. The aim of this study was to investigate how the revised WHO classification affects our practice in diagnosing these lymphomas in children.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We retrospectively reviewed cases of mature HGBCL diagnosed at our hospital between 2015 and 2018.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 14 mature HGBCL cases with BL morphological features, 11 showed\n MYC<\/jats:italic>\n rearrangement consistent with BL and 3 were\n MYC<\/jats:italic>\n -negative. Two\n MYC<\/jats:italic>\n -negative cases showed regions of 11q gain and loss by microarray consistent with Burkitt-like lymphoma with 11q aberration (BLL-11q). The third\n MYC<\/jats:italic>\n -negative case showed diffuse and strong MUM1 expression, translocation involving 6p25 by chromosome analysis and\n IRF4<\/jats:italic>\n rearrangement by fluorescence in situ hybridisation analysis consistent with large B-cell lymphoma with\n IRF4<\/jats:italic>\n rearrangement (LBL-IRF4). All patients were treated according to applicable chemotherapeutic protocols and achieved remission.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n BLL-11q and LBL-IRF4, two newly defined entities, should be considered in paediatric\n MYC<\/jats:italic>\n -negative mature HGBCL cases. Accurate diagnosis needs careful histopathological examination and proper cytogenetic testing. Since they have unique cytogenetic features, specific treatments for them may emerge in the future. Therefore, accurate diagnosis based on the 2016 WHO classification is clinically significant.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/jclinpath-2019-206267","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T17:15:25Z","timestamp":1579626925000},"page":"563-570","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Application of 2016 WHO classification in the diagnosis of paediatric high-grade\n MYC<\/i>\n -negative mature B-cell lymphoma with Burkitt-like morphological features"],"prefix":"10.1136","volume":"73","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"},{"name":"Department of Pathology and Laboratory Medicine, University of Kansas, Kansas City, Kansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel M","family":"Bowen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda D","family":"Cooley","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Repnikova","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A","family":"Gener","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Garola","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J","family":"August","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Allyson","family":"Hays","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Zwick","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-5473","authenticated-orcid":false,"given":"Weijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Children\u2019s Mercy Hospitals and Clinics, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"2025120519344657000_73.9.563.1","unstructured":"Swerdlow SH , Campo E , Harris NL , et al . World Health organization classification of tumours of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon, France: International Agency for Research on Cancer, 2017."},{"key":"2025120519344657000_73.9.563.2","unstructured":"Kluin P , Harris N , Stein H . B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH , Campo E , Harris NL , eds. Who classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon, France: IARC Press, 2008: 265\u20136."},{"key":"2025120519344657000_73.9.563.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2025120519344657000_73.9.563.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-297879"},{"key":"2025120519344657000_73.9.563.5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12343"},{"key":"2025120519344657000_73.9.563.6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11899-010-0076-4","article-title":"Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?","volume":"6","author":"Thomas","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"2025120519344657000_73.9.563.7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181bb9a18"},{"key":"2025120519344657000_73.9.563.8","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.589"},{"key":"2025120519344657000_73.9.563.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5827"},{"key":"2025120519344657000_73.9.563.10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bjh.14011","article-title":"Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma","volume":"173","author":"Miles","year":"2016","journal-title":"Br J Haematol"},{"key":"2025120519344657000_73.9.563.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136465"},{"key":"2025120519344657000_73.9.563.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-767335"},{"key":"2025120519344657000_73.9.563.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507996"},{"key":"2025120519344657000_73.9.563.14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124305"},{"key":"2025120519344657000_73.9.563.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-864025"},{"key":"2025120519344657000_73.9.563.16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ajcp\/aqx139","article-title":"The 11q-Gain\/Loss aberration occurs recurrently in MYC-Negative Burkitt-like lymphoma with 11q aberration, as well as MYC-Positive Burkitt lymphoma and MYC-Positive high-grade B-cell lymphoma, NOS","volume":"149","author":"Grygalewicz","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"2025120519344657000_73.9.563.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330795"},{"key":"2025120519344657000_73.9.563.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1855-z"},{"key":"2025120519344657000_73.9.563.19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207928"},{"key":"2025120519344657000_73.9.563.20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cancergen.2015.12.005","article-title":"The peculiar 11q-gain\/loss aberration reported in a subset of MYC-negative high-grade B-cell lymphomas can also occur in a MYC-rearranged lymphoma","volume":"209","author":"Havelange","year":"2016","journal-title":"Cancer Genet"},{"key":"2025120519344657000_73.9.563.21","unstructured":"Huttle K , Ott G . An aggressive Burkitt-Like lymphoma. SH 2017-0137. Chicago: SH Workshop, 2017."},{"key":"2025120519344657000_73.9.563.22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/modpathol.2017.186","article-title":"A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration","volume":"31","author":"Rymkiewicz","year":"2018","journal-title":"Mod Pathol"},{"key":"2025120519344657000_73.9.563.23","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22014"},{"key":"2025120519344657000_73.9.563.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-206267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:34:55Z","timestamp":1764992095000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-206267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/jclinpath-2019-206267"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-206267","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]}}}